FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q1 2024

SEC EDGAR SourceSEC Filings

Top Holdings175 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
SPYSPY
PUT

STATE STREET SPDR S&P 500 ETF TRUST CL USD INC

11.5M$6B25.6%
Decreased

HESS CORP

6.4M$981.5M4.2%
2 qtrssince 2023-Q4
Increased
94

PIONEER NATURAL RESOURCE

3.5M$924M3.9%
2 qtrssince 2023-Q4
Increased
66

UNITEDHEALTH GROUP INC

1.7M$841.7M3.6%$458.87+4.00%
5 qtrssince 2023-Q1
Increased
78

IQVIA HOLDINGS INC

2.8M$717.2M3.0%$164.12+54.09%
22 qtrssince 2018-Q4
Decreased
0

EXELIXIS INC

26.7M$633.1M2.7%$19.10+24.25%
22 qtrssince 2018-Q4
Increased
54

SALESFORCE.COM INC

2M$588M2.5%$175.19+70.07%
18 qtrssince 2019-Q4
Increased
55

ARAMARK

17.8M$579.6M2.5%$25.90+23.13%
14 qtrssince 2020-Q4
Increased
57

NASDAQ OMX GROUP/THE

8.4M$532.4M2.3%$57.63+7.04%
3 qtrssince 2023-Q3
Increased
67

MICROSOFT CORP

1.2M$509.7M2.2%$214.60+93.53%
22 qtrssince 2018-Q4
Decreased
0

ALPHABET INC-CL C

3.3M$508.2M2.2%$101.61+48.73%
22 qtrssince 2018-Q4
Increased
57

TRANSUNION

6.4M$506.8M2.2%$86.03-8.05%
22 qtrssince 2018-Q4
Decreased
0

NEW YORK TIMES CO-A

11.2M$483.5M2.1%$41.34+2.15%
16 qtrssince 2020-Q2
Increased
63
IBBIBB
PUT

ISHARES BIOTECHNOLOGY ETF

3.5M$480.3M2.0%
New

THERMO FISHER SCIENTIFIC INC

797,416$463.5M2.0%$432.36+33.68%
18 qtrssince 2019-Q4
Decreased
0

WABTEC CORP

3M$430.7M1.8%$82.10+75.95%
22 qtrssince 2018-Q4
Decreased
0

CBRE GROUP INC - A

4.2M$406.9M1.7%$73.86+31.65%
3 qtrssince 2023-Q3
Decreased
0

NATERA INC

3.9M$359.2M1.5%$59.78+52.99%
12 qtrssince 2021-Q2
Increased
55

INTUIT INC

537,078$349.1M1.5%$383.35+67.39%
6 qtrssince 2022-Q4
Increased
49

S&P GLOBAL INC

793,844$337.7M1.4%$318.41+31.88%
8 qtrssince 2022-Q2
Decreased
0
$23.6B
AUM
175
Positions
Q1 2024
Filing
Rating · 1.5
Quarterly Portfolio Change
-7%Q4'22$16.9B+8%Q1'23$18.3B+9%Q2'23$19.9B+8%Q3'23$21.4B+2%Q4'23$21.9B+8%Q1'24$23.6B
Activity profile
$ moved · Q1'24
New22%Increased37%Decreased23%Exited18%
Composition
Equity vs derivatives
Equity72%Puts28%Calls0%
Holding period
Avg 2.1 years
<1Q18%1-4Q18%1-2Y11%2Y+53%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $23.6B across 175 positions as of Q1 2024. Top holdings: SPY (25.6%), HES (4.2%), PXD (3.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.

Q1 2024 Summary

Active quarter - 41 new positions, 26 exits, 38 increased. Top move: HES (INCREASED, conviction 94). Portfolio: $23.6B across 175 positions.

Top holdings by portfolio weight

Total AUM$17B
HES4.16%
PXD3.92%
UNH3.57%
IQV3.04%
EXEL2.69%
CRM2.49%
ARMK2.46%
NDAQ2.26%
MSFT2.16%
GOOG2.16%
Other2.15%

Portfolio allocation by GICS sector

Sectors11
Healthcare35.67%
Unknown15.94%
Technology13.91%
Financial Services12.17%
Industrials8.04%
Communication Services5.96%
Real Estate4.34%
Consumer Cyclical1.79%
Basic Materials1.63%
Consumer Defensive0.41%
Other0.13%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown, Technology
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track Record60
Conviction43
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q3 2024 Q2 2026+8.5M shares+$314.1M
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 Q2 2026+9M shares+$755.7M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used